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Severity of von Willebrand DiseaseAlexander Tischer,1 Pranathi Madde,1 Laurie Moon-Tasson,1 and Matthew Auton1,*
1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MinnesotaABSTRACT The primary hemostatic von Willebrand factor (vWF) functions to sequester platelets from rheological blood flow
and mediates their adhesion to damaged subendothelium at sites of vascular injury. We have surveyed the effect of 16 disease-
causing mutations identified in patients diagnosed with the bleeding diathesis disorder, von Willebrand disease (vWD), on the
structure and rheology of vWF A1 domain adhesiveness to the platelet GPIba receptor. Thesemutations have a dynamic pheno-
typical range of bleeding from lack of platelet adhesion to severe thrombocytopenia. Using new rheological tools in combination
with classical thermodynamic, biophysical, and spectroscopic metrics, we establish a high propensity of the A1 domain to
misfold to pathological molten globule conformations that differentially alter the strength of platelet adhesion under shear
flow. Rheodynamic analysis establishes a quantitative rank order between shear-rate-dependent platelet-translocation pause
times that linearly correlate with clinically reported measures of patient platelet counts and the severity of thrombocytopenia.
These results suggest that specific secondary structure elements remaining in these pathological conformations of the A1
domain regulate GPIba binding and the strength of vWF-platelet interactions, which affects the vWD functional phenotype
and the severity of thrombocytopenia.INTRODUCTION‘‘Diathesis’’ refers to the tendency to suffer from a medical
condition, particularly a ‘‘hereditary or fundamental predis-
position to a state or condition of disease or a disorder
involving structural or metabolic abnormalities.’’ von Wille-
brand disease (vWD) constitutes a very common bleeding
diathesis with an estimated epidemiological prevalence of
~1% of the human population (1). Over the course of the
last few decades, clinical diagnostics have enabled the clas-
sification of this disorder into three distinct types (vWD types
1–3) of vonWillebrand factor (vWF) deficiency. vWF, amul-
timeric glycoprotein secreted from the vascular endothelium,
mediates platelet adhesion to exposed subendothelial con-
nective tissue and contributes to the arrest of bleeding during
primary hemostasis. It consists of multiple copies of A, B, C,
and D domains that are arranged in the order D0-D3-A1-A2-
A3-D4-B1-B2-B3-C1-C2-(cysteine knot).
Type-1 and type-3 vWD results in partial or complete
quantitative deficiencies of vWF from blood plasma. The
qualitative functional deficiencies of vWF associated with
type-2 vWD result in one of the following: defective inter-
actions between theA1 domain and theGPIba platelet recep-
tor, loss of hemostatic activity due to abnormal multimer
proteolysis of the A2 domain by the ADAMTS-13 plasma
protease, or deficient binding of the D domains to FVIII.
Type-1 vWD accounts for ~65–80% of cases; type-2
vWD, ~20–35%; and type-3 is extremely rare (2). Of 399Submitted January 31, 2014, and accepted for publication July 9, 2014.
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0006-3495/14/09/1185/11 $2.00unique mutations identified in the vWF gene associated
with vWD, 160 are associated with type-2 vWD and 54 of
these directly affect binding between A1 and GPIba (3) in
the vWD subtypes 2B and 2M. These subtypes categorically
represent either an increased (2B) or reduced/deficient (2M)
vWF-dependent platelet adhesion. Missense mutations in
these vWD subtypes have a dynamic range of clinical man-
ifestations from a paucity of vWF-platelet interactions to
severe thrombocytopenia resulting in bleeding at both ex-
tremes of vWF dysfunction.
From the time of early observations of impaired platelet
adhesion to the subendothelium in vWD (4) and following
the isolation and characterization of the vWF gene, protein,
and domain structure (5–7), the general perception has been
that mutations affecting the adhesion of platelets to vWF
alter the conformation of the A1 domain. This idea has
been prevalent even in the early literature describing the
patients afflicted by the specific missense amino-acid sub-
stitutions causing the disease. Type 2B mutations were pre-
sumed to alter the conformation of vWF multimers and
increase exposure of the GPIb binding site (8) such that
vWF could mimic the effect of subendothelial matrix or
collagen binding, causing pathologic spontaneous platelet
aggregation (SPA) (9).
Conversely, a complete loss-of-function, type 2M muta-
tion was thought to inhibit the normal allosteric regulation
of GPIb binding (10). The concept of allosterism took pre-
cedence as more mutations were identified and the regula-
tion of vWF interaction with platelet GPIb was thought to
involve an equilibrium between binding-competent andhttp://dx.doi.org/10.1016/j.bpj.2014.07.026
1186 Tischer et al.incompetent states. More recently, it has been suggested that
type 2M mutations could destabilize the global fold of the
A1 domain resulting in loss of function (11–13). The first
evidence of distinctly different GPIb binding conformations
in the recombinant A1 domain was observed when reduc-
tion and alkylation of the disulfide bond enhanced GPIb
binding affinity and reversed the shear flow dependency of
platelet adhesion (14,15).
Our initial studies took a thermodynamic perspective
when we directly observed a stable, partially unfolded inter-
mediate conformation of the A1 domain in the denaturant
unfolding pathway (16). To model this intermediate, we
reduced-and-carboxyamidated (RCAM) the A1 domain
and found increased affinity for platelet GPIb. Combined
with unfolding studies of A1 harboring a few mutations,
we developed a thermodynamic cycle that described the
A1-GPIb interaction in terms of an equilibrium between
low- and high-affinity conformations. This model was
consistent with previous concepts of allosterism while
bringing protein folding to the forefront of the issue, but it
did not account for situations in which the A1 domain could
misfold to inactive conformations (17,18). Recently we
have demonstrated that RCAM A1 exists in a molten
globule state, a conformation lacking global tertiary struc-
ture while retaining secondary and potential supersecondary
structure elements. These structural elements in RCAM A1
are sufficient to maintain high affinity for GPIb such that
platelets remain firmly attached under shear flow (19).
Here, we illustrate that the predisposition of the platelet
GPIba binding A1 domain of vWF is toward a partially
disordered molten globule state involving mutation-induced
structural abnormalities that specifically alter the shear-
dependent function of vWF. We have recombinantly engi-
neered 16 of the most commonly reported type 2B and
2M mutations into the A1 domain of vWF and compared
their effect on shear-dependent platelet adhesion and the
conformational and thermodynamic properties of A1. All
proteins excepting five type 2M variants of the A1 domain
supported shear-flow-dependent platelet adhesion to sur-
face-captured A1 domain variants in a parallel plate flow-
chamber. We have analyzed the strength of platelet adhesionBiophysical Journal 107(5) 1185–1195by taking the statistical average of pause-time distributions,
a measure of the average time platelets remain immobile
under shear flow. These pause times are significantly
correlated to reported vWD patient platelet counts (R2 ¼
0.88) and the severity of thrombocytopenia indicating the
structural and functional properties of the isolated A1
domain variants are representative of plasma vWF platelet
interactions.
Using established conformational metrics (19), only six
of the 18 variants (including WT and RCAM A1) are
natively structured, and 10 of the remaining 12 variants
are molten globules. One type 2M mutation reduced platelet
adhesion relative to WT, five type 2M mutations resulted
in molten globules with a complete loss of function, and
four type 2B mutations induced molten globule states that
differentially enhance platelet pause times under rheological
shear flow. The structural locations of these mutations in the
A1 domain (Fig. 1) suggest that allosteric effects in addition
to localized effects of mutations on the a2-helix loop a3-
helix may regulate the adhesive strength of the A1-GPIba
tether bond. Our results provide the first experimental evi-
dence, to our knowledge, of A1 domain misfolding to disor-
dered conformations and indicate that the pathobiological
function of the vWF A1 domain depends on secondary
structure elements remaining in these disordered states.MATERIALS AND METHODS
Mutagenesis, expression, purification, and quantification treatments of the
vWF A1 variants are described in the Supporting Material.Biophysical, structural, and thermodynamic
metrics
Circular dichroism measurements were performed on a model No. 420C
circular-dichroism spectrometer (Aviv Biomedical, Lakewood Township,
NJ). All fluorescence (FL) measurements were performed on a Fluorolog
3 spectrofluorometer (HORIBA Jobin-Yvon, Edison, NJ) equipped with a
model No. LF1-3751 temperature controller (Wavelength Electronics,
Bozeman, MT). Near- and far-ultraviolet (UV) circular dichroism (CD),
intrinsic protein FL, and ANS (8-anilino naphthalene sulfonic acid)
CD spectra were determined as described in Tischer et al. (19). UreaFIGURE 1 Structure of the A1 domain in com-
plex with GPIba with locations of type 2B (red)
and 2M (blue) vWD mutations (A) and colored
by conformational class (B); native (same color
as A1 structure), nativelike (yellow), and molten
globule (orange). (Helices 2 and 3 are also indi-
cated in orange.) The tryptophan residue is indi-
cated for reference to FL studies. PDB:1SQ0. See
Movie S1 in the Supporting Material. We used
CHIMERA, Ver. 8.6.1 (https://www.cgl.ucsf.edu/
chimera/). To see this figure in color, go online.
A Protein Folding Disease Affecting Primary Hemostasis 1187denaturation (monitored by far-UV CD) and thermal denaturation (moni-
tored by far-UV CD, intrinsic protein FL, and ANS FL) were performed
and analyzed as previously described (19,20). Acrylamide quenching of
intrinsic tryptophan fluorescence was performed and analyzed as described
in Tischer et al. (19). All spectra were collected at 20C.Parallel plate flow-chamber studies
The rheological interaction of platelets with A1 domain variants harboring
type 2M and type 2B mutations was studied using recently developed flow-
chamber methods (19). The A1 domains (5 mM) were immobilized on
Vena8 biochips (Cellix, Dublin, Ireland) coated with a Cu2þ-chelated poly-
ethylene-glycol surface serviced by MicroSurfaces, Inc. (Englewood, NJ)
via the 6His-Tag, enabling the preservation of the structural properties
of the domain in solution and its concomitant effects on platelet adhesion
under rheological shear flow. One-hundred microliters of citrated whole
blood, obtained from the informed consent of normal healthy volunteer
donors with approval from the Mayo Clinic Institutional Review Board
(Rochester, MN), was perfused at a shear rate of 800 s1 followed by
Tris-buffered saline. Platelets translocating on the surface-captured do-
mains were filmed at 24 frames/s for 1 min at logarithmic intervals of the
shear rate. Coordinates obtained from tracking analysis of the resulting
movies were processed using our recently developed statistical analytics
for the quantification of cellular adhesion dynamics across immobilized
receptors under rheological shear flow (19). Biochips lacking the surface-
captured A1 domain were completely inert to platelets.FIGURE 2 Urea denaturation (A) and thermal denaturation (B) of the
A1 domain monitored by CD at 222 nm for the representative variants
indicated. (Red) Gain-of-function, type-2B. (Blue) Loss-of-function, type-
2M. To see this figure in color, go online.RESULTS
Thermodynamic and conformational
characterization of types 2M and 2B vWF
A1 domain variants
We began these studies by assessing the effects of mutations
on the thermodynamic stability of A1 (18) and developed a
framework that incorporated partial unfolding as a means
for enhancing the binding affinity of A1 for GPIba (17).
Initially, we used the urea-temperature phase diagram
method for assessing the reversible thermodynamics of un-
folding at various temperatures (18,21), and more recently
we have incorporated thermal denaturations to assess kinetic
irreversibility (20,22). We have employed these methods
using a variety of spectroscopic observables that assess the
conformation of these A1 domain variants as a function of
temperature and urea.
These observables include the following:
1. Far-UV CD to assess secondary structure content,
2. Near-UV CD to assess tertiary structure content,
3. Intrinsic protein FL to assess solvent exposure of tyro-
sine and tryptophan residues,
4. Acrylamide quenching of tryptophan FL to assess local
solvent exposure of the single tryptophan residue, and
5. Binding of the molten globule indicator-dye, ANS,
to assess exposure of hydrophobic surface area.
In total, these studies have provided metrics that are able to
classify the conformation of A1 into three types, based on
biophysical spectroscopy, as follows:Natively structured
In this class, the A1 domain is in its global native fold, but
mutations induce local conformations in the native state
ensemble that alter its thermodynamic stability against
partial unfolding toward an intermediate conformation.
The type 2B mutations R1306Q and I1309V and the type
2M mutation G1324S have previously been characterized
in this conformational class (18). In addition, R1308L and
I1372S also belong to this class.
Nativelike
In this class, the A1 domain has reduced secondary structure
content, but retains some of the tertiary structure required
for a cooperative urea- or temperature-induced protein
unfolding transition. The type 2M mutation A1437T and
the type 2B mutation R1341Q belong to this class.
Molten globule
In this class, the A1 domain has a significantly reduced
tertiary structure content as defined by the absence of a
cooperative urea- or temperature-induced protein unfolding
transition and retains only secondary and/or supersecondary
structure. The type 2M mutations F1369I, E1359K, I1425F,
S1285F, and R1374H, and the type 2B mutations H1268D,
P1337L, V1316M, and V1314D, belong to this class.
Fig. 2 and Fig. S1, Fig. S2, Fig. S3, and Fig. S4 in the
Supporting Material illustrate urea and thermal denatur-
ations of type 2M and type 2B mutations from each confor-
mational class monitored by Far-UV CD, intrinsic protein
FL, and ANS FL for all A1-domain variants studied.
Thermodynamic analysis (see Table S1 in the Supporting
Material) of the native variants generally demonstrates that
the stability is decreased relative to WT A1 for type 2B
gain-of-function variants and the stability is increased for
loss of function variants. This is also evident in the unfold-
ing transition midpoints, T* and c1/2, which are lower for
gain-of-function and higher for loss-of-function variants.
The T* and c1/2 values are also positively correlated soBiophysical Journal 107(5) 1185–1195
1188 Tischer et al.that a change in thermal stability is paralleled by a compa-
rable change in urea stability (see Fig. S5). These results
remain in general agreement with our previous conclusions
(17,18). The nativelike variants, A1437T and R1341Q, also
have low stability, but because they are less structured, some
regions of the A1 domain are likely to be partially unfolded.
Intrinsic protein FL is generally not sensitive to confor-
mational differences between natively structured and native-
like conformations because the FL intensities are similar in
both pre- and postthermal unfolding transitions. However,
ANS FL does discriminate between these conformations,
because the mutations result in exposure of new hydropho-
bic groups in the A1 domain.
Far-UV and near-UV CD spectra demonstrate reduced
secondary structure and a significantly diminished tertiary
structure content in molten globules (see Fig. S6). These
conformations show an ellipticity in the far-UV that gradu-
ally increases with urea and temperature without a sigmoid
transition. The type-2M variants, E1359K and F1369I, are
the most disordered having ellipticities that are greater
than all other variants over the full range of urea and temper-
ature. All other molten globule states have conformations
with similar secondary structure content as the urea and
thermally unfolded WT A1 domain. P1337L and H1268D
are the most structured molten globules. We consider these
as borderline with the nativelike class because, although
they do not have a urea-induced unfolding transition, ther-
mal denaturation shows a hint of a sigmoid transition at
around 50C by CD, suggesting a slightly more organized
cluster of supersecondary structure under native conditions.
Intrinsic protein FL intensity of the molten globule variants
is higher than native and nativelike variants in the low
temperature range, indicating that tyrosine and tryptophan
residues are maximally exposed. Likewise, ANS FL inten-
sities of the molten globule class are greater than those for
the native and nativelike variants, indicating a greater expo-
sure of hydrophobic groups in the domain.
The spectroscopic metrics used to assess the conforma-
tional properties of the A1 domain variants are summarized
in Fig. 3, and are also given as follows:
1. The far-UV ellipticity at 222 nm is used as a metric for
global a-helical secondary structure content in all
domain variants (Fig. 3, A and B).
2. The Stern-Volmer constant of collisional acrylamide
quenching of tryptophan fluorescence is a measure of
tryptophan solvent exposure within the local tertiary
structure of all domain variants (Fig. 3, C and D). The
greater the magnitude of this constant, the more sol-
vent-exposed the tryptophan, and the greater its suscep-
tibility to fluorescence quenching (see Fig. S7).
3. After thermal denaturation, the A1 domain becomes irre-
versibly trapped in the molten globule conformation
(20), which binds ANS with greater affinity than folded
conformations of A1. The ratio of maximal ANS FLBiophysical Journal 107(5) 1185–1195intensity at ~475 nm before and after thermal denatur-
ation is used as a metric for the degree of hydrophobicity
of the domain relative to that in the postthermal molten
globule state (Fig. 3, E and F). A ratio close to 1 indicates
that the domain variant exists as a molten globule in its
natural conformation.
Fig. 3 illustrates that these A1 domain variants each have
a particular conformational character with respect to these
metrics. Ellipticity distinguishes the domain variants as
either having native or nonnative secondary structure con-
tent. With respect to the tertiary environment of the trypto-
phan, all molten globules have quenching constants in the
range of 4–5/M; RCAM A1 is ~6/M due to the absence of
a disulfide bond. The native and nativelike classes have a
greater variability in the quenching constant, and, depend-
ing on the location, the mutation could either directly or
allosterically affect tryptophan exposure by destabilizing
the local region. Similarly, there is much more variability
in the ANS intensity ratio in the native and nativelike class
depending on localized exposure of the hydrophobic groups
induced by the mutations. In general, these metrics are high-
ly correlated with each other among all domain variants
(Fig. 4), indicating that losses of secondary and tertiary
structure are mutually consequential.Shear-flow-dependent platelet adhesion to
types 2M and 2B vWF A1 domain variants
The pause (residence) time for which a platelet remains
immobile is a fundamental parameter obtained from our
analysis of the shear-dependent platelet translocations, and
is directly proportional to the strength and number of A1-
GPIba bonds. The shear-rate dependency of this parameter
correlates with the force-dependent lifetimes of single A1-
GPIba bonds (17,20, 23–25). Fig. 5 shows the statistical
mean 5 standard deviation of the shear-rate-dependent
pause times. Fig. 5 A illustrates representative pause times
obtained as a function of shear rate for a type 2B
(P1337L) and a type 2M (A1437T) mutation relative to
WT A1. Shear-dependent pause times were determined for
all A1 variants capable of binding platelets (Fig. 5, C–E)
categorized according to their experimentally determined
conformational classification. In Fig. 5 B, the platelet pause
times obtained for all variants at the physiological shear rate
of 1500 s1 are ranked from least to greatest, ranging from
~0.3 to 3.5 s (see also Table 1). Of the type 2M mutations
studied, F1369I, E1359K, I1425F, R1374H, and G1324S
did not bind platelets. All type 2B mutations, with the
exception of R1308L, bind tighter than the WTA1 domain,
resulting in higher pause times at all shear rates. These data
demonstrate that the absolute magnitude of the pause time
varies considerably with the particular mutation.
We have compiled platelet counts obtained from routine
complete blood counts and ristocetin cofactor-dependent
FIGURE 3 Biophysical metrics for secondary
and tertiary structure. (A) Far-UV CD spectra.
(B) CD ellipticity at 222 nm. (C) Stern-Volmer
plots. (D) Stern-Volmer collisional quenching con-
stants. (E) Normalized ANS FL spectra of native
and thermally denatured A1 domain variants. (F)
ANS intensity ratios. (Red) Type 2B and (blue)
type 2M in panels A, C, and E. (B, D, and F) All
variants are ranked according to increasing pause
time as in Fig. 5. (Black) Natively structured vari-
ants. (Dark gray) Nativelike variants. (Light gray)
Molten globule variants. (White) RCAM A1. To
see this figure in color, go online.
A Protein Folding Disease Affecting Primary Hemostasis 1189vWF activity relative to vWF antigen (vWF:RCo/vWF:Ag)
ratios from clinical case reports (see Table S2), summarized
in Table 1with vWFmultimer analysis and unique symptoms.
Platelet counts are reported at baseline before any stress-FIGURE 4 Correlation between biophysical metrics for secondary and tertiar
0.82). (B and C) Ellipticity versus ANS intensity ratios (R2 ¼ 0.77) and Stern
To see this figure in color, go online.inducing condition, such as pregnancy or desmopressin
administration, when such conditions were reported. Type
2Mpatients typically have below-normal vWF:RCo/vWF:Ag
ratios, normal platelet counts (150–400  103mL1), normaly structure. (A) Stern-Volmer constants versus ANS intensity ratios (R2 ¼
-Volmer constants (R2 ¼ 0.82). (Red) 2B; (blue) 2M; (white) RCAM A1.
Biophysical Journal 107(5) 1185–1195
FIGURE 5 (A) Shear-rate dependency of platelet pause times on normal (WTA1), type 2B (P1337L), and type 2M (A1437T) variants. (B) Rank order of
pause times at 1500 s1 shear rate from least to greatest. The type 2M variants F1369I, E1359K, I1425F, S1285F, and R1374H did not bind platelets at any
shear rate. (Solid) Natively structured variants. (Dark shaded) Nativelike variants. (Light shaded) Molten globule variants. (Open) RCAM A1 represents a
case of firm adhesion with no platelet translocation due to loss of the disulfide bond (19). Shear-rate dependency of platelet pause times on (C) natively
structured type 2B A1 domain variants, (D) natively structured type 2M A1 domain variants, and (E) molten globule A1 domain variants. To see this figure
in color, go online.
1190 Tischer et al.vWFmultimerization, decreased or absent ristocetin-induced
platelet binding (RiPB), and either normal or decreased
platelet binding induced by the snake venom botrocetin
(BiPB). Type 2B patients typically have normal to diminished
vWF:RCo/vWF:Ag ratios, vWF multimers lacking high-mo-
lecular-weight (HMW) species, platelet counts ranging from
normal to severely thrombocytopenic, and in some cases,
spontaneous platelet aggregation,which occurs in the absence
of shear stress.
In Fig. 6, the mean 5 standard deviation of all reported
platelet counts and vWF:RCo /vWF:Ag ratios are plotted
as a function of our experimentally determined mean 5
standard deviation platelet pause times at 1500 s1.
Although many of the platelet counts are within the normal
range, Fig. 6 A demonstrates a linear correlation with a
coefficient of determination R2 ¼ 0.88. Mutations with the
highest pause times (I1309V, V1316M, and V1314D) vary
from moderate to severe thrombocytopenia. This high level
of correlation demonstrates that the pause times determined
from our experimental system are of diagnostic quality in
that they trend with thrombocytopenic severity. This trendBiophysical Journal 107(5) 1185–1195indicates that the functional and conformational properties
of the single A1 domain are representative of the intrinsic
properties governing the interaction between platelet
GPIb and multimeric vWF in vivo. Conversely, vWF:RCo/
vWF:Ag ratios are not correlative to experimental pause
times (Fig. 6 B), and there is no correlation between
vWF:RCo/vWF:Ag and platelet count (R2 ¼ 0.06).DISCUSSION
A considerable challenge for accurate diagnoses of qualita-
tive vWD subtypes remains prominent. Although the rare
type-3 quantitative deficiency can be identified by the
virtual absence of plasma vWF using vWF:Ag tests, the
more common type-1 quantitative and type-2 qualitative
deficiencies are more prone to subtype misdiagnosis
due to disconcordance of vWF:RCo activity relative to
vWF:Ag (28). Thrombocytopenia is a strong indicator of
type 2B, but it need not be present for mild variants. Distin-
guishing type 2M is usually dependent on the absence
of ristocetin-induced platelet agglutination (RIPA) and a
TABLE 1 Structure/Function properties of type-2 vWD variants of the A1 domain and their clinical manifestations in vWD patients
Mutation
(vWD type)a
A1 domain
conformationb
Pause time
1500 s1 (s)c vWF:RCo/vWF:Agd
Patient platelet
count ( 103/mL)d
Patient vWF
multimerse Unique symptomsf
F1369I (2M) MG NB (2) 0.345 0.19 (4) NR Normal Y RiPB, normal BiPB
E1359K (2M) MG NB (2) 0.55 (1) NR NR Y RiPB, normal BiPB
I1425F (2M) MG NB (2) 0.345 0.2 (4) NR Normal Y RiPB, normal BiPB
S1285F (2M) MG NB (2) 0.395 0.05 (3) 3485 55 (3) Y HMW Y RiPB, Y BiPB
R1374H (2M) MG NB (2) 0.365 0.18 (50) 2395 56 (6) Y HMW with ATS Y RiPB, Y BiPB
G1324S (2M)g N NB (3) 0.315 0.13 (4) 2785 47 (3) Normal Absent RiPB, normal BiPB
A1437T (2M) NL 0.285 0.07 (3) 0.475 0.04 (4) NR NR Mild moderate bleeding
R1308L (2B) N 0.295 0.03 (5) 0.885 0.17 (16) 2985 85 (11) Normal Y Collagen binding
WTA1 N 0.675 0.07 (6) 0.7–1.2 150–400 Normal Normal
R1341Q (2B) NL 0.945 0.06 (5) 0.565 0.18 (27) 1885 85 (23) Absent HMW Moderate bleeding with TCP
R1306Q (2B) N 0.955 0.1 (3) 0.735 0.14 (5) 2195 36 (5) Normal Mild TCP
I1372S (2B) N 1.035 0.004 (2) 0.825 0.13 (2) 2565 33 (2) Normal SPA
H1268D (2B) MG 1.265 0.17 (4) 0.615 0.21 (5) 2085 79 (8) Y HMW Intermittent mild TCP
P1337L (2B) MG 1.565 0.005 (4) 0.845 0.22 (10) 1655 84 (7) Y HMW Moderate TCP
I1309V (2B) N 2.145 0.23 (3) 0.725 0.09 (14) 1095 11 (13) Normal SPA and persistent moderate TCP
V1316M (2B) MG 2.945 0.07 (4) 0.455 0.25 (47) 775 63 (26) Absent HMW Chronic severe TCP
V1314D (2B) MG 3.535 0.19 (3) 0.25 (1) 455 50 (1) Absent HMW Severe TCP
aSee the Supporting Material for literature reporting patient clinical data.
bN, native (native structure with varying thermodynamic stability); NL, nativelike (defined by a reduced secondary structure content with a urea and thermal
unfolding transition); and MG, molten globule (defined by lack of a urea and thermal unfolding transition).
cNB, no binding. Pause times are reported as the mean5 SD of the number of experimental measurements made in parentheses.
dClinical data reported as the mean5 SD of all reported data in the referenced literature (see Table S1 for the primary literature data). The number of reported
values are in parentheses. NR, not reported. vWF:RCo/vWF:Ag ratio and platelet counts are reported for a similar G1324A substitution.
eHMW, high molecular weight; ATS, abnormal triplet structure.
fRiPB, ristocetin-induced platelet binding; BiPB, botrocetin-induced platelet binding; SPA, spontaneous platelet aggregation; TCP, thrombocytopenia. Ad-
jectives describing TCP are quoted directly from the authors.
gSome clinical data also included from the analogous mutation G1324A due to insufficient clinical data on G1324S.
A Protein Folding Disease Affecting Primary Hemostasis 1191normal multimer analysis, although some variants can
reduce HMW multimers. Type 2B can have reduced or ab-
sent HMW multimers but not in all cases, and enhanced
RIPA can usually distinguish type 2B from type 2A. Conse-
quently, the results of all these tests must be carefully and
statistically compared relative to one another, making accu-
rate diagnosis of type-2 vWD subtypes difficult.
The measurement of vWF ristocetin cofactor activity is a
common diagnostic test performed in clinics worldwide,
quantifying the ability of a patient’s plasma to agglutinate
platelets in the presence of the antibiotic, ristocetin. This
diagnostic is normalized to vWF antigen, a measure of
the plasma concentration of vWF. A quantitative correla-
tion between platelet pause times and vWF:RCo/vWF:Agratios (Fig. 6 B) was not expected because of high clinical
interlaboratory variance (~20–50%) (29–32). Ristocetin
was quickly removed from clinical practice due to the hap-
hazardous thrombocytopenia and blood clotting resulting
from the agent (33,34). This hematologic complication
initially proved useful as a research tool for the investiga-
tion of platelet aggregation (35) leading to its prevalent use
in clinical diagnostic standards worldwide. However,
vWF:RCo activity is the worst performing assay of its class
because of its imprecision, poor limit of detection (28,36),
and the fact that it was not initially designed as a functional
diagnostic. Rather, it was originally intended to detect the
absence of a clotting factor associated with FVIII before
vWF was known to be the factor responsible for diseaseFIGURE 6 (A) Platelet counts reported for vWD
patients with known mutations as a function of the
platelet pause times obtained at 1500 s1 shear rate
shown in Fig. 5. The linearity has a correlation
coefficient of determination (R2 ¼ 0.88). (B) The
ratio of vWF ristocetin cofactor activity relative
to vWF antigen levels reported for vWD patients.
(Gray areas) Normal range of these clinical met-
rics. (Red) Type 2B; (blue) type 2M. Data points
at zero pause time represent the type 2M mutations
for which there was no shear-dependent binding.
These data are also tabulated in Table 1 with the
primary clinical data given in Table S1. To see
this figure in color, go online.
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1192 Tischer et al.(37,38). Despite some monoclonal antibody evidence
for ristocetin binding to distinct sites on vWF (39,40),
ristocetin’s action is not specific because it binds many pro-
teins, particularly within proline and glycine-containing
b-turn regions, and flocculates many large polymeric pro-
teins (41).
A fundamental limitation of today’s functional diagnos-
tics is that they cannot account for the conformational
dynamics of the protein structures involved in the rheolog-
ical binding between platelets and vWF. Recognizing these
limitations, the Biorheology Scientific Subcommittee of
the International Society of Thrombosis and Hemostasis
(Carrboro, NC), has considered the potential use of
shear-flow assays in phenotyping vWD (42,43). We have
demonstrated that platelet pause times do quantitatively
correlate to reported vWD patient platelet counts and the
severity of thrombocytopenia (Fig. 6 A). This is a prom-
ising observation because it indicates that the functional
and structural effects of these particular amino-acid sub-
stitutions in the single A1 domain are representative of
their effects in multimeric plasma vWF (11). In addition,
it illustrates that our method of flow-chamber surface che-
lation preserves the innate conformation of the A1 domains
without complications due to nonspecific surface adsorp-
tion. The correlation also emphasizes the dynamic range
of pause times attainable by these domain variants. Rather
than shifting the shear rate dependencies to higher or lower
tether forces as previously shown by single molecule mea-
surements (17,18,23), these mutations specifically alter the
conformation of the A1 domain in ways that pathologically
alter the strength of platelet adhesion at all shear rates. The
effect of raising or lowering the pause time magnitude over
the full range of physiological shear necessitates a fresh
perspective on the rheology and structure of the A1:GPIba
tether bond.
Following crystal structure determinations of WT A1
(44), two type 2B variants (R1306Q and I1309V) (45),
and their complexes with GPIba (46–48), many molecular
dynamics simulations have been performed (23,49–52).
However, the starting structures and those resulting from
these simulations are representative of only local confor-
mational changes within the native state ensemble, and the
forced dissociation of the complex cannot account for
misfolded conformations. Because >60% of the variants
described here are not natively structured, it is clear that
the A1 domain has a significant propensity to misfold.
Although the global native fold is not significantly different
between WT, R1306Q, and I1309V (20), it is possible that
the local structural changes observed in silico could repre-
sent events that lead to a molten globule state with enhanced
function. Within the natively-structured class, the gain-of-
function variants R1306Q and I1309V show local changes
in the a1-b2-loop (47) and the internalization of a water
molecule as a wedge between this loop and the a2-helix
(48), respectively.Biophysical Journal 107(5) 1185–1195These conformational differences are likely a result of the
loss of a R1306 salt bridge to D1451 in the a6-helix and a
loss of hydrophobic interactions between I1309 and P1337
at the beginning of the a2-helix. Molecular dynamics has
recently shown that these mutations result in a pendulum-
like movement of the a2-helix away from the domain
with the largest deviation occurring at the N-terminus.
These conformational changes could increase its propensity
for unfolding under shear stress (53). Our structural studies
show that, although the secondary structure content of these
variants is unchanged, these mutations increase accessibility
of the tryptophan and moderately enhance the exposed
hydrophobic surface area (Fig. 3, D and F). Functionally,
the effect of I1309V on platelet pause times is more severe
than R1306Q, presumably because of the more direct and
localized effect on the a2-helix hydrophobic packing.
The P1337L mutation occurring at the N-terminus of the
a2-helix induces a molten globule state that has enhanced
platelet pause times. This could be due to a loss of localized
polyproline-II structure constraining the backbone- and/or
hydrophobic-packing problems imposed by the leucine
side chain. The reduced secondary structure content and
enhanced tryptophan accessibility and hydrophobic surface
area of this variant imply that the structure and stability of
the a2-helix could be perturbed. Similarly, the nativelike
R1341Q variant is the least thermodynamically stable and
its position in the a2-helix may eliminate salt-bridge con-
tacts with either E1305 in a1-helix or the N-terminal
E1264. This could result in destabilization of the a2-helix
and enhance its propensity to unfold under shear stress.
In molecular dynamics, dissociation of the a2-helix was
accompanied by a salt-bridge switch from R1341-E1305
to R1341-E1264 (53).
The V1314D and V1316M variants in the b2-strand
have the largest pause times and are associated with the
most severe thrombocytopenias observed in vWD patients.
Refolding of these molten globule variants is highly
improbable due to either the insertion of a negatively
charged aspartate or methionine-induced steric hindrances
in the hydrophobic core. Given that the valine side chains
are directed toward a1- and a2-helices, these substitutions
have substantial effects on the tertiary structural contacts
holding this region together. Taking into account all the
variants that cluster in this region, it is probable that the
a2-helix is inhibitory to GPIba binding, and destabilization
or unfolding of this helix leads to an enhanced capacity to
bind platelets under shear stress.
Conversely, the native R1308L variant represents an
anomaly in that it is clinically assigned as a type 2B
mutation despite normal bleeding times, vWF multimers,
vWF:RCo/vWF:Ag ratios, and the absence of thrombocyto-
penia in patients (26,27,54). The only evidence for a type 2B
phenotype was low RIPA and reduced collagen binding
(26,55). However, in our system it clearly has reduced
platelet function because platelet pause times are shorter
A Protein Folding Disease Affecting Primary Hemostasis 1193than those obtained with WTA1. R1308L is natively struc-
tured and induces local increases in tryptophan accessibility
and hydrophobic surface area due to the removal of R1308-
W1313 stacking interactions and substitution of the leucine
side chain. Reduced platelet adhesiveness to this variant
might be explained by the enhanced thermodynamic stabil-
ity due to efficient hydrophobic packing within the a1-b2-
loop region. Therefore, we reclassify R1308L as belonging
to subtype 2M.
An intriguing observation is that molten globule confor-
mations can also result in completely disabled platelet adhe-
sive function. The I1425F and S1285F variants that occur
in the a5-helix and b1-a1-loop, respectively, introduce large
hydrophobic packing interferences due to the imposed
phenyl side chain and globally misfold and inactivate the
A1 domain. Additionally, two specific variants in this class,
E1359K and F1369I, located adjacent to the binding site in
the a3-helix, result in the most disordered molten globule
conformations. Similar to another type 2M K1362T muta-
tion (56), the charge reversal in E1359K may disrupt a helix
stabilizing salt bridge between E1359 and K1362. Further-
more, the a3-helix, which appears to be anchored to the
domain by hydrophobic interactions with F1369, is destabi-
lized by the F1369I substitution. In the loop following the
a3-helix, R1374H may disrupt a potential salt bridge to
D1277 in the b1-strand. Given the location of E1359K
and F1369I, the a3-helix may stabilize structural contacts
that enable binding and the more distant I1425F and S1285F
mutations may allosterically affect this region and/or other
regions required for binding.
G1324S is the only type 2M mutation that remains
natively structured, and it is the most thermodynamically
stable of the variants investigated here. Interpreting how
this variant causes complete loss of function, based on
structure alone, remains elusive because the location is
solvent-exposed. In the complex, this region directly
hydrogen-bonds with the GPIba b-hairpin. A possible
mechanism is that glycine enhances conformational fluctu-
ations and allows protein structures to sample locally
unfolded states in the energy landscape without changing
the ground-state structure (57). Substitution of a serine
effectively reduces the f-j conformational space, intro-
ducing rigidity into this region of structure. Rigidity is
also artificially introduced here in the WTA1 domain crys-
tal structure by chelation of divalent Cd2þ between H1322
and H1326, and the b-hairpin of GPIba forces rigidity by
continuing the central b-sheet in the cocrystal complex
(44). Another mechanism might also be that placing a side
chain containing amino acid in position 2 of a type-I b-
hairpin turn is unfavorable, because glycine predominantly
occurs in this position. Therefore, serine could simply desta-
bilize the b-turn and prevent antiparallel b-strand hydrogen
bonds necessary for binding to GPIba in the native state.
The fact that both gain- and loss-of-function molten glob-
ules occur in the A1 domain supports the idea that specificstructural elements are required for the A1-GPIba interac-
tion whereas others elements are inhibitory. Although the
possibility of binding-induced refolding of the A1 to the
native state from the molten globule state exists, this sce-
nario is not probable because the forces on vWF resulting
from shear stress of blood flow and tensile stress of platelet
adhesion favor less-ordered conformations (58). Further-
more, a relaxed conformation of the A1 domain induced
by carboxyamidation of the disulfide bond, which is inca-
pable of refolding, results in such tight binding of GPIb to
remaining secondary structure elements that platelets
become arrested under shear flow (19). Inspection of the
structural locations of these mutations and their effect on
the functional and conformational properties of the A1
domain suggests that the a2- and a3-helices are probable
secondary structure elements involved in misfolding to
pathological conformations of the A1 domain. However, it
is clear that mutations distant from the binding site also
affect structure and function indicating that allosterism con-
tributes in addition to more localized structural effects.SUPPORTING MATERIAL
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